Stock data

Onesource Specl Pharma L share price

ONESOURCE on NSE · data as of 16 Oct 2026

₹1,407.80Close · −1.77%
₹1,925.0052-week high · 3 Nov 2025
₹1,057.0052-week low · 30 Jan 2026
−26.9%from 52-week high
−24.7%1-year return
₹34.8 cravg daily turnover (20 days)

Onesource Specl Pharma L closed at ₹1,407.80 on 16 Oct 2026 (−1.77% on the day). It is 26.9% below its 52-week high of ₹1,925.00 (3 Nov 2025) and 33.2% above its 52-week low of ₹1,057.00 (30 Jan 2026). The stock has underperformed the Nifty 50 over the past year (-24.7% vs -8.5%). It is trading below both its 50-day and 200-day averages (a downtrend), with RSI 22 (oversold zone).

Where the price sits

52W low ₹1,057.0052W high ₹1,925.00

Last 12 months

Weekly closing prices, adjusted for splits and bonus issues.

Returns vs Nifty 50

PeriodONESOURCENifty 50Difference
1 week−3.7%+2.8%−6.5 pts
1 month−11.8%−0.3%−11.5 pts
3 months−14.8%−4.9%−9.9 pts
6 months−6.5%−4.3%−2.2 pts
1 year−24.7%−8.5%−16.2 pts

Trend and activity

  • 50-day average: ₹1,539.72 (price below)
  • 200-day average: ₹1,569.56 (price below)
  • RSI (14 days): 22
  • Turnover on 16 Oct 2026: ₹14.7 cr (0.5x the 20-day average volume)

New to these terms? See 52-week high, moving average and RSI.

Quick answers

What is the 52-week high of Onesource Specl Pharma L?

The 52-week high of Onesource Specl Pharma L (ONESOURCE) is ₹1,925.00, reached on 3 Nov 2025. The 52-week low is ₹1,057.00, on 30 Jan 2026 (NSE, as of 16 Oct 2026).

How has Onesource Specl Pharma L performed in the last year?

Over the last year the share price has moved -24.7%, compared with -8.5% for the Nifty 50 (as of 16 Oct 2026). Past returns do not predict future returns.

Is Onesource Specl Pharma L in an uptrend?

As of 16 Oct 2026, Onesource Specl Pharma L is trading below both its 50-day and 200-day averages (a downtrend), with RSI 22 (oversold zone). Trend describes the past, not what happens next.

Price facts only, refreshed every trading day. Not a recommendation to buy or sell. Education only. Not investment advice. All stocks · Today's stock lists